Bariki Rajasekhar, Haranath Chinthaginjala
Abstract: Background: Poor adherence and suboptimal therapeutic results are common
challenges in the management of Alzheimer’s disease, indicating an urgent need for
alternative drug delivery strategies to enhance treatment optimization and
patient compliance. Objectives: To
develop in-vivo label transdermal
pharmaceutical films containing Memantine (MMT) and Donepezil (DPZ) for
improved patient compliance and optimized drug therapy in Alzheimer’s disease. Methods: The films were prepared
with PVP K30, modified chitosan and HPMC K15. Among the various formulations
evaluated in-vitro and in-vivo, the most promising, TDP-11, was
selected. Six healthy adult male New Zealand white rabbits were used to assess
the drug's availability from the patches; blood samples were collected for
pharmacokinetic studies. Results: The transdermal patches TDP-1 to
TDP-15 displayed uniform weights (115-132 mg) and thickness measurements
between 0.22-0.31 mm; The folding endurance reached a range of 160 to 270 and
their pH level, which is safe for skin use, measured between 5.7 and 6.5; The
swelling capacity reached 165% and their moisture vapor transmission rate ranged
from 220 to 450 g/m2/h. The drug content reached a high level, ranging
from 97.5 to 99.8 %, while the substance absorbed moisture at a rate of 91.7 to
99.5 % and lost moisture at a rate of 1.8 to 6.2 %. The TDP-11 patch showed
superior performance through its maximum flux of 18.5 μg/cm²/h and its
permeability of 0.07 cm/h, which outperformed both DPZ (3.1±0.05) and MMT
(4.2±0.04). Animal testing in 6 rabbits showed that the optimized TDP-11
achieved maximum blood concentration and maximum absorption time at 6 h with
complete systemic absorption. Conclusion: This investigation shows that the
films offer controlled release of the drug. The higher pharmacokinetic
parameters of the TDP-11 formulation also suggest that these patches are an
attractive and efficient alternative to intact oral drug administration, especially
suited for pretension administration.

Alzheimer’s disease
Delivery
Donepezil
Memantine
Transdermal